利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.03 秒)

    Bezazepine derivatives as &agr;v integrin receptor antagonists
    3.
    发明授权
    Bezazepine derivatives as &agr;v integrin receptor antagonists 失效
    贝沙西平衍生物作为alphav整合素受体拮抗剂

    公开(公告)号：US06232308B1

    公开(公告)日：2001-05-15

    申请号：US09496525

    申请日：2000-02-02

    申请人： Ben C. Askew

    发明人： Ben C. Askew

    IPC分类号： A61K315513

    CPC分类号： C07D491/04

    摘要： The present invention relates to benzazepine derivatives and their use as &agr;v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3, &agr;v&bgr;5, and/or &agr;v&bgr;6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.

    摘要翻译： 本发明涉及苯并氮杂衍生物及其作为alphav整联蛋白受体拮抗剂的用途。 更具体地说，本发明的化合物是整联蛋白受体alphavbeta3，alphavbeta5和/或alphavbeta6的拮抗剂，可用于抑制骨吸收，治疗和预防骨质疏松，抑制血管再狭窄，糖尿病性视网膜病变，黄斑变性，血管生成，动脉粥样硬化 ，炎症，伤口愈合，病毒性疾病，肿瘤生长和转移。

    Novel Compounds and Uses Thereof
    7.
    发明申请
    Novel Compounds and Uses Thereof 有权
    新型化合物及其用途

    公开(公告)号：US20160137646A1

    公开(公告)日：2016-05-19

    申请号：US14894214

    申请日：2014-05-30

    申请人： Ben C. ASKEW ,  Andrew GOOD ,  Kala Pharmaceuticals, Inc.

    发明人： Winston Zapanta Ong ,  Pawel Wojciech Nowak ,  Ben C. Askew ,  Andrew Good

    IPC分类号： C07D487/04 ,  C07D519/00

    CPC分类号： C07D487/04 ,  C07D519/00

    摘要： The present invention provides novel compounds of any one of Formulae (I)-(IV), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of any one of Formulae (I)-(IV) and pharmaceutical compositions thereof that are mucus penetrating. The invention also provides methods and kits for using the inventive compounds, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor signaling pathway (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.

    摘要翻译： 本发明提供式（I） - （IV）中任一项的新化合物及其药物组合物。 还提供了包含粘液穿透的式（I） - （IV）中任一项的化合物及其药物组合物的颗粒（例如纳米颗粒）。 本发明还提供了用于使用本发明化合物及其药物组合物用于治疗和/或预防与生长因子信号传导途径的异常或病理性血管生成和/或异常信号传导相关的疾病的方法和试剂盒（例如，血管内皮生长因子 VEGF）），例如增殖性疾病（例如癌症，良性肿瘤，炎症性疾病，自身免疫性疾病）和眼部疾病（例如，黄斑变性，青光眼，糖尿病性视网膜病变，视网膜母细胞瘤，水肿，葡萄膜炎，干眼症，睑炎炎， 手术炎症）。

    Integrin receptor antagonists
    10.
    发明授权
    Integrin receptor antagonists 失效
    整合素受体拮抗剂

    公开(公告)号：US06413955B1

    公开(公告)日：2002-07-02

    申请号：US09677677

    申请日：2000-10-02

    申请人： Ben C. Askew ,  Garry R. Smith

    发明人： Ben C. Askew ,  Garry R. Smith

    IPC分类号： A61K3155

    CPC分类号： C07D471/04 ,  A61K31/437 ,  A61K31/44 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3 and/or &agr;v&bgr;5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth.

    摘要翻译： 本发明涉及其化合物及其衍生物，其合成及其作为玻连蛋白受体拮抗剂的用途。 更具体地说，本发明的化合物是整联蛋白受体alphavbeta3和/或alphavbeta5的拮抗剂，可用于抑制骨吸收，治疗和预防骨质疏松症，抑制血管再狭窄，糖尿病性视网膜病变，黄斑变性，血管生成，动脉粥样硬化，炎症性关节炎 ，癌症和转移性肿瘤生长。